167 related articles for article (PubMed ID: 34471161)
1. Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1.
Shahinozzaman M; Ahmed S; Emran R; Tawata S
Sci Rep; 2021 Sep; 11(1):17471. PubMed ID: 34471161
[TBL] [Abstract][Full Text] [Related]
2. 1,2,3-Triazolyl ester of Ketorolac: A "Click Chemistry"-based highly potent PAK1-blocking cancer-killer.
Nguyen BCQ; Takahashi H; Uto Y; Shahinozzaman MD; Tawata S; Maruta H
Eur J Med Chem; 2017 Jan; 126():270-276. PubMed ID: 27889630
[TBL] [Abstract][Full Text] [Related]
3. Both triazolyl ester of ketorolac (15K) and YM155 inhibit the embryonic angiogenesis in ovo (fertilized eggs) via their common PAK1-survivin/VEGF signaling pathway.
Ahn MR; Bae JY; Jeong DH; Takahashi H; Uto Y; Maruta H
Drug Discov Ther; 2017; 11(6):300-306. PubMed ID: 29332887
[TBL] [Abstract][Full Text] [Related]
4. 1,2,3-Triazolyl ester of ketorolac (15K): Boosting both heat-endurance and lifespan of C. elegans by down-regulating PAK1 at nM levels.
Nguyen BC; Kim SA; Won SM; Park SK; Uto Y; Maruta H
Drug Discov Ther; 2018; 12(2):92-96. PubMed ID: 29760342
[TBL] [Abstract][Full Text] [Related]
5. 1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice.
Hennig R; Albawardi A; Almarzooqi S; Haneefa S; Imbaraj E; Zaaba NE; Nemmar A; Subramanya S; Maruta H; Adrian TE
Drug Discov Ther; 2019 Nov; 13(5):248-255. PubMed ID: 31656252
[TBL] [Abstract][Full Text] [Related]
6. From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
Maruta H; Ahn MR
Eur J Med Chem; 2017 Dec; 142():229-243. PubMed ID: 28814374
[TBL] [Abstract][Full Text] [Related]
7. 1,2,3-Triazolyl esterization of PAK1-blocking propolis ingredients, artepillin C (ARC) and caffeic acid (CA), for boosting their anti-cancer/anti-PAK1 activities along with cell-permeability.
Takahashi H; Nguyen BCQ; Uto Y; Shahinozzaman M; Tawata S; Maruta H
Drug Discov Ther; 2017 May; 11(2):104-109. PubMed ID: 28442677
[TBL] [Abstract][Full Text] [Related]
8. Identification of Pak1 inhibitors using water thermodynamic analysis.
Biswal J; Jayaprakash P; Suresh Kumar R; Venkatraman G; Poopandi S; Rangasamy R; Jeyaraman J
J Biomol Struct Dyn; 2020 Jan; 38(1):13-31. PubMed ID: 30661460
[TBL] [Abstract][Full Text] [Related]
9. A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1).
Shahinozzaman M; Ishii T; Ahmed S; Halim MA; Tawata S
J Biomol Struct Dyn; 2020 Aug; 38(12):3514-3526. PubMed ID: 31448698
[TBL] [Abstract][Full Text] [Related]
10. Engineering Pak1 Allosteric Switches.
Dagliyan O; Karginov AV; Yagishita S; Gale ME; Wang H; DerMardirossian C; Wells CM; Dokholyan NV; Kasai H; Hahn KM
ACS Synth Biol; 2017 Jul; 6(7):1257-1262. PubMed ID: 28365983
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
12. Water Mapping and Scoring Approaches to Predict the Role of Hydration Sites in the Binding Affinity of PAK1 Inhibitors.
Biswal J; Jayaprakash P; Rayala SK; Venkatraman G; Rangasamy R; Poopandi S; Jeyakanthan J
Comb Chem High Throughput Screen; 2022; 25(4):660-676. PubMed ID: 33687876
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer.
El-Baba C; Mahadevan V; Fahlbusch FB; Mohan S S; Rau TT; Gali-Muhtasib H; Schneider-Stock R
Mol Cancer; 2014 Aug; 13():201. PubMed ID: 25174975
[TBL] [Abstract][Full Text] [Related]
14. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.
Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS
J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101
[TBL] [Abstract][Full Text] [Related]
15. Old drug new tricks: Chlorhexidine acts as a potential allosteric inhibitor toward PAK1.
Huang HW; Zhang XY; Song PL; Jiang HL; Li W; Wang PL; Wang J; Liu FN
Biochem Biophys Res Commun; 2018 Jan; 495(1):728-732. PubMed ID: 29146188
[TBL] [Abstract][Full Text] [Related]
16. [Computer-aided prediction and molecular mechanism investigation of active components in compound Kushen injection inhibiting p21-activated kinase 1].
Lin L; Chang J; Tian Y; Chen J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2024 Apr; 41(2):313-320. PubMed ID: 38686412
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
18. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.
Viaud J; Peterson JR
Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886
[TBL] [Abstract][Full Text] [Related]
19. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.
Deacon SW; Beeser A; Fukui JA; Rennefahrt UE; Myers C; Chernoff J; Peterson JR
Chem Biol; 2008 Apr; 15(4):322-31. PubMed ID: 18420139
[TBL] [Abstract][Full Text] [Related]
20. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
